表紙
市場調査レポート

Lexicon Pharmaceuticals, Inc.の製品パイプライン分析

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 240929
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Lexicon Pharmaceuticals, Inc.の製品パイプライン分析 Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 44 Pages
概要

Lexicon Pharmaceuticals, Inc.は、糖尿病やカルチノイド症候群といった疾患用医薬品の創薬、研究に携わるバイオテクノロジー企業です。

当レポートでは、Lexicon Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Lexicon Pharmaceuticals, Inc.の基本情報

Lexicon Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Lexicon Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Lexicon Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Lexicon Pharmaceuticals, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Lexicon Pharmaceuticals, Inc.:薬剤プロファイル

  • telotristat etiprate
  • LX-1033
  • LX-2931
  • sotagliflozin
  • LX-7101
  • LX-2761
  • S100-A8

Lexicon Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Lexicon Pharmaceuticals, Inc.:最近のパイプライン動向

Lexicon Pharmaceuticals, Inc.:休止中のプロジェクト

Lexicon Pharmaceuticals, Inc.:企業発表

Lexicon Pharmaceuticals, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04872CDB

Global Markets Direct's, 'Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Lexicon Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lexicon Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lexicon Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lexicon Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lexicon Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Lexicon Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lexicon Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lexicon Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lexicon Pharmaceuticals, Inc. Snapshot
    • Lexicon Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Lexicon Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Lexicon Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products Glance
    • Lexicon Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Lexicon Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Lexicon Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Lexicon Pharmaceuticals, Inc. - Drug Profiles
    • telotristat etiprate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-1033
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-2931
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotagliflozin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-7101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-2761
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S100-A8
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lexicon Pharmaceuticals, Inc. - Pipeline Analysis
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Target
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Lexicon Pharmaceuticals, Inc. - Dormant Projects
  • Lexicon Pharmaceuticals, Inc. - Company Statement
  • Lexicon Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lexicon Pharmaceuticals, Inc., Key Information
  • Lexicon Pharmaceuticals, Inc., Key Facts
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase III, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase II, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase I, 2014
  • Lexicon Pharmaceuticals, Inc. - Preclinical, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Lexicon Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Lexicon Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top